Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 18 de 18
Filter
Add more filters










Publication year range
1.
Int J Mol Sci ; 23(3)2022 Jan 25.
Article in English | MEDLINE | ID: mdl-35163299

ABSTRACT

NMSC (non-melanoma skin cancer) is a common tumor in the Caucasian population, accounting for 90% of skin cancers. Among them, squamous cell carcinomas (SCCs) can metastasize and, due to its high incidence, constitute a severe health problem. It has been suggested that cutaneous SCCs with more risk to metastasize express high levels of nuclear IKKα. However, the molecular mechanisms that lead to this enhanced aggressiveness are largely unknown. To understand in depth the influence of nuclear IKKα in skin SCC progression, we have generated murine PDVC57 skin carcinoma cells expressing exogenous IKKα either in the nucleus or in the cytoplasm to further distinguish the tumor properties of IKKα in both localizations. Our results show that IKKα promotes changes in both subcellular compartments, resembling EMT (epithelial-mesenchymal transition), which are more pronounced when IKKα is in the nucleus of these tumor cells. These EMT-related changes include a shift toward a migratory phenotype and induction of the expression of proteins involved in cell matrix degradation, cell survival and resistance to apoptosis. Additionally, we have found that apigenin, a flavonoid with anti-cancer properties, inhibits the expression of IKKα and attenuates most of the pro-tumoral EMT changes induced by IKKα in mouse tumor keratinocytes. Nevertheless, we have found that apigenin only inhibits the expression of the IKKα protein when it is localized in the cytoplasm.


Subject(s)
Apigenin/pharmacology , I-kappa B Kinase/metabolism , Skin Neoplasms/metabolism , Animals , Apigenin/metabolism , Carcinoma/genetics , Carcinoma/metabolism , Carcinoma/pathology , Carcinoma, Squamous Cell/pathology , Cell Line, Tumor , Cell Movement/genetics , Cell Nucleus/metabolism , Cytoplasm/metabolism , Epithelial-Mesenchymal Transition/physiology , Gene Expression/genetics , Gene Expression Regulation, Neoplastic/genetics , I-kappa B Kinase/genetics , Keratinocytes/metabolism , Mice , Signal Transduction/genetics , Skin/metabolism , Skin Neoplasms/genetics , Skin Neoplasms/pathology
2.
Cells ; 10(8)2021 07 27.
Article in English | MEDLINE | ID: mdl-34440675

ABSTRACT

Ageing is a complex process, induced by multifaceted interaction of genetic, epigenetic, and environmental factors. It is manifested by a decline in the physiological functions of organisms and associated to the development of age-related chronic diseases and cancer development. It is considered that ageing follows a strictly-regulated program, in which some signaling pathways critically contribute to the establishment and maintenance of the aged state. Chronic inflammation is a major mechanism that promotes the biological ageing process and comorbidity, with the transcription factor NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) as a crucial mediator of inflammatory responses. This, together with the finding that the activation or inhibition of NF-κB can induce or reverse respectively the main features of aged organisms, has brought it under consideration as a key transcription factor that acts as a driver of ageing. In this review, we focused on the data obtained entirely through the generation of knockout and transgenic mouse models of either protein involved in the NF-κB signaling pathway that have provided relevant information about the intricate processes or molecular mechanisms that control ageing. We have reviewed the relationship of NF-κB and premature ageing; the development of cancer associated with ageing and the implication of NF-κB activation in the development of age-related diseases, some of which greatly increase the risk of developing cancer.


Subject(s)
Aging, Premature/metabolism , Aging/metabolism , Inflammation Mediators/metabolism , NF-kappa B/metabolism , Neoplasms/metabolism , Age Factors , Aging/genetics , Aging/pathology , Aging, Premature/genetics , Aging, Premature/pathology , Animals , Disease Models, Animal , Gene Expression Regulation, Neoplastic , Humans , Mice, Transgenic , NF-kappa B/genetics , Neoplasms/genetics , Neoplasms/pathology , Signal Transduction
3.
Int J Mol Sci ; 22(13)2021 Jun 23.
Article in English | MEDLINE | ID: mdl-34201751

ABSTRACT

Cylindromatosis (CYLD) is a deubiquitinase (DUB) enzyme that was initially characterized as a tumor suppressor of adnexal skin tumors in patients with CYLD syndrome. Later, it was also shown that the expression of functionally inactive mutated forms of CYLD promoted tumor development and progression of non-melanoma skin cancer (NMSC). However, the ability of wild-type CYLD to inhibit skin tumorigenesis in vivo in immunocompetent mice has not been proved. Herein, we generated transgenic mice that express the wild type form of CYLD under the control of the keratin 5 (K5) promoter (K5-CYLDwt mice) and analyzed the skin properties of these transgenic mice by WB and immunohistochemistry, studied the survival and proliferating characteristics of primary keratinocytes, and performed chemical skin carcinogenesis experiments. As a result, we found a reduced activation of the nuclear factor kappa B (NF-κB) pathway in the skin of K5-CYLDwt mice in response to tumor necrosis factor-α (TNF-α); accordingly, when subjected to insults, K5-CYLDwt keratinocytes are prone to apoptosis and are protected from excessive hyperproliferation. Skin carcinogenesis assays showed inhibition of tumor development in K5-CYLDwt mice. As a mechanism of this tumor suppressor activity, we found that a moderate increase in CYLD expression levels reduced NF-κB activation, which favored the differentiation of tumor epidermal cells and inhibited its proliferation; moreover, it decreased tumor angiogenesis and inflammation. Altogether, our results suggest that increased levels of CYLD may be useful for anti-skin cancer therapy.


Subject(s)
Carcinoma, Squamous Cell/pathology , Deubiquitinating Enzyme CYLD/genetics , Skin Neoplasms/pathology , Animals , Carcinoma, Squamous Cell/blood supply , Carcinoma, Squamous Cell/genetics , Cell Differentiation/genetics , Cell Proliferation/genetics , Cells, Cultured , Deubiquitinating Enzyme CYLD/metabolism , Genes, Tumor Suppressor , Immunocompetence , Keratinocytes/drug effects , Keratinocytes/pathology , Mice, Inbred C57BL , Mice, Inbred DBA , Mice, Transgenic , NF-kappa B/metabolism , Neovascularization, Pathologic/genetics , Phorbol Esters/toxicity , Skin Neoplasms/blood supply , Skin Neoplasms/genetics , Tumor Necrosis Factor-alpha/metabolism , Tumor Necrosis Factor-alpha/pharmacology
4.
Comput Struct Biotechnol J ; 17: 251-262, 2019.
Article in English | MEDLINE | ID: mdl-30867890

ABSTRACT

Lung cancer is the leading worldwide cause of cancer mortality, however, neither curative treatments nor substantial prolonged survival has been achieved, highlighting the need for investigating new proteins responsible for its development and progression. IKKα is an essential protein for cell survival and differentiation, which expression is enhanced in human non-small cell lung cancer (NSCLC) and correlates with poor patient survival, appearing as a relevant molecule in lung cancer progression. However, there are not conclusive results about its role in this type of cancer. We have recently found that IKKα performs different functions and activates different signaling pathways depending on its nuclear or cytoplasmic localization in tumor epidermal cells. In this work, we have studied the involvement of IKKα in lung cancer progression through the generation of lung cancer cell lines expressing exogenous IKKα either in the nucleus or in the cytoplasm. We demonstrate that IKKα signaling promotes increased cell malignancy of NSCLC cells as well as lung tumor progression and metastasis in either subcellular localization, through activation of common protumoral proteins, such as Erk, p38 and mTor. But, additionally, we found that depending on its subcellular localization, IKKα has non-overlapping roles in the activation of other different pathways known for their key implication in lung cancer progression: while cytoplasmic IKKα increases EGFR and NF-κB activities in lung tumor cells, nuclear IKKα causes lung tumor progression through c-Myc, Smad2/3 and Snail activation. These results suggest that IKKα may be a promising target for intervention in human NSCLC.

5.
Aging (Albany NY) ; 11(1): 127-159, 2019 01 10.
Article in English | MEDLINE | ID: mdl-30631004

ABSTRACT

CYLD is a deubiquitinating enzyme known for its role as a tumor suppressor whose mutation leads to skin appendages tumors and other cancers. In this manuscript we report that the tumor suppressor CYLD, similarly to other renowned tumor suppressor genes, protects from premature aging and cancer. We have generated transgenic mice expressing the mutant CYLDC/S protein, lacking its deubiquitinase function, under the control of the keratin 5 promoter, the K5-CYLDC/S mice. These mice express the transgene in different organs, including those considered to be more susceptible to aging, such as skin and thymus. Our results show that K5-CYLDC/S mice exhibit epidermal, hair follicle, and sebaceous gland alterations; and, importantly, they show signs of premature aging from an early age. Typically, 3-month-old K5-CYLDC/S mice exhibit a phenotype characterized by alopecia and kyphosis, and, the histological examination reveals that transgenic mice show signs of accelerated aging in numerous organs such as skin, thymus, pancreas, liver and lung. Additionally, they spontaneously develop tumors of diverse origin. Over-activation of the NF-κB pathway, along with hyperactivation of Akt, JNK and c-Myc, and chronic inflammation, appear as the mechanisms responsible for the premature aging of the K5-CYLDC/S mice.


Subject(s)
Aging, Premature/genetics , Deubiquitinating Enzyme CYLD/metabolism , Hair Follicle/growth & development , Neoplasms/etiology , Animals , Cell Line , Cyclin-Dependent Kinase Inhibitor p16/genetics , Cyclin-Dependent Kinase Inhibitor p16/metabolism , Deubiquitinating Enzyme CYLD/genetics , Gene Expression Regulation/physiology , Humans , Keratinocytes/physiology , Mice , Mice, Transgenic , Mutation , NF-kappa B , Promoter Regions, Genetic , Skin Aging/genetics , Thymus Gland/physiology , Tumor Necrosis Factor-alpha/genetics , Tumor Necrosis Factor-alpha/metabolism
8.
Mol Cancer Res ; 15(9): 1255-1264, 2017 09.
Article in English | MEDLINE | ID: mdl-28584022

ABSTRACT

IKKß (encoded by IKBKB) is a protein kinase that regulates the activity of numerous proteins important in several signaling pathways, such as the NF-κB pathway. IKKß exerts a protumorigenic role in several animal models of lung, hepatic, intestinal, and oral cancer. In addition, genomic and proteomic studies of human tumors also indicate that IKBKB gene is amplified or overexpressed in multiple tumor types. Here, the relevance of IKKß in skin cancer was determined by performing carcinogenesis studies in animal models overexpressing IKKß in the basal skin layer. IKKß overexpression resulted in a striking resistance to skin cancer development and an increased expression of several tumor suppressor proteins, such as p53, p16, and p19. Mechanistically, this skin tumor-protective role of IKKß is independent of p53, but dependent on the activity of the Ink4a/Arf locus. Interestingly, in the absence of p16 and p19, IKKß-increased expression favors the appearance of cutaneous spindle cell-like squamous cell carcinomas, which are highly aggressive tumors. These results reveal that IKKß activity prevents skin tumor development, and shed light on the complex nature of IKKß effects on cancer progression, as IKKß can both promote and prevent carcinogenesis depending on the cell type or molecular context.Implications: The ability of IKKß to promote or prevent carcinogenesis suggests the need for further evaluation when targeting this protein. Mol Cancer Res; 15(9); 1255-64. ©2017 AACR.


Subject(s)
Cyclin-Dependent Kinase Inhibitor p16/metabolism , I-kappa B Kinase/biosynthesis , Skin Neoplasms/metabolism , Tumor Suppressor Protein p14ARF/metabolism , Animals , Cyclin-Dependent Kinase Inhibitor p16/genetics , Epigenesis, Genetic , I-kappa B Kinase/genetics , Mice , Mice, Transgenic , Mutation , Skin Neoplasms/genetics , Skin Neoplasms/pathology , Tumor Suppressor Protein p14ARF/genetics , Tumor Suppressor Protein p53/genetics , Tumor Suppressor Protein p53/metabolism
10.
Cancer Res ; 77(6): 1357-1368, 2017 03 15.
Article in English | MEDLINE | ID: mdl-28108518

ABSTRACT

RAS genes are mutated in 20% of human tumors, but these mutations are very rare in breast cancer. Here, we used a mouse model to generate tumors upon activation of a mutagenic T2Onc2 transposon via expression of a transposase driven by the keratin K5 promoter in a p53+/- background. These animals mainly developed mammary tumors, most of which had transposon insertions in one of two RASGAP genes, neurofibromin1 (Nf1) and RAS p21 protein activator (Rasa1). Immunohistochemical analysis of a collection of human breast tumors confirmed that low expression of RASA1 is frequent in basal (triple-negative) and estrogen receptor negative tumors. Bioinformatic analysis of human breast tumors in The Cancer Genome Atlas database showed that although RASA1 mutations are rare, allelic loss is frequent, particularly in basal tumors (80%) and in association with TP53 mutation. Inactivation of RASA1 in MCF10A cells resulted in the appearance of a malignant phenotype in the context of mutated p53. Our results suggest that alterations in the Ras pathway due to the loss of negative regulators of RAS may be a common event in basal breast cancer. Cancer Res; 77(6); 1357-68. ©2017 AACR.


Subject(s)
Biomarkers, Tumor/metabolism , DNA Transposable Elements/genetics , Transposases/physiology , Triple Negative Breast Neoplasms/pathology , Tumor Suppressor Protein p53/physiology , p120 GTPase Activating Protein/metabolism , Animals , Apoptosis , Biomarkers, Tumor/genetics , Cell Proliferation , Cells, Cultured , Female , Humans , Mice , Mice, Transgenic , Neoplasm Staging , Prognosis , Triple Negative Breast Neoplasms/genetics , Triple Negative Breast Neoplasms/metabolism , p120 GTPase Activating Protein/genetics
11.
Oncotarget ; 7(47): 76779-76792, 2016 11 22.
Article in English | MEDLINE | ID: mdl-27732959

ABSTRACT

IKKα plays a mandatory role in keratinocyte differentiation and exerts an important task in non-melanoma skin cancer development. However, it is not fully understood how IKKα exerts these functions. To analyze in detail the role of IKKα in epidermal stratification and differentiation, we have generated tridimensional (3D) cultures of human HaCaT keratinocytes and fibroblasts in fibrin gels, obtaining human skin equivalents that comprise an epidermal and a dermal compartments that resembles both the structure and differentiation of normal human skin. We have found that IKKα expression must be strictly regulated in epidermis, as alterations in its levels lead to histological defects and promote the development of malignant features. Specifically, we have found that the augmented expression of IKKα results in increased proliferation and clonogenicity of human keratinocytes, and leads to an accelerated and altered differentiation, augmented ability of invasive growth, induction of the expression of oncogenic proteins (Podoplanin, Snail, Cyclin D1) and increased extracellular matrix proteolytic activity. All these characteristics make keratinocytes overexpressing IKKα to be at a higher risk of developing skin cancer. Comparison of genetic profile obtained by analysis of microarrays of RNA of skin equivalents from both genotypes supports the above described findings.

12.
Oncotarget ; 7(20): 29531-47, 2016 May 17.
Article in English | MEDLINE | ID: mdl-27121058

ABSTRACT

Nonmelanoma skin cancers (NMSC) are the most common human malignancies. IKKα is an essential protein for skin development and is also involved in the genesis and progression of NMSC, through mechanisms not fully understood. While different studies show that IKKα protects against skin cancer, others indicate that it promotes NMSC. To resolve this controversy we have generated two models of transgenic mice expressing the IKKα protein in the nucleus (N-IKKα mice) or the cytoplasm (C-IKKα mice) of keratinocytes. Chemical skin carcinogenesis experiments show that tumors developed by both types of transgenic mice exhibit histological and molecular characteristics that make them more prone to progression and invasion than those developed by Control mice. However, the mechanisms through which IKKα promotes skin tumors are different depending on its subcellular localization; while IKKα of cytoplasmic localization increases EGFR, MMP-9 and VEGF-A activities in tumors, nuclear IKKα causes tumor progression through regulation of c-Myc, Maspin and Integrin-α6 expression. Additionally, we have found that N-IKKα skin tumors mimic the characteristics associated to aggressive human skin tumors with high risk to metastasize. Our results show that IKKα has different non-overlapping roles in the nucleus or cytoplasm of keratinocytes, and provide new targets for intervention in human NMSC progression.


Subject(s)
Cell Nucleus/enzymology , Cytoplasm/enzymology , I-kappa B Kinase/metabolism , Keratinocytes/pathology , Skin Neoplasms/pathology , Animals , Carcinoma, Basal Cell/enzymology , Carcinoma, Basal Cell/pathology , Carcinoma, Squamous Cell/enzymology , Carcinoma, Squamous Cell/pathology , Humans , Keratinocytes/enzymology , Mice , Mice, Transgenic , Skin Neoplasms/enzymology
13.
Oncotarget ; 7(15): 20902-18, 2016 Apr 12.
Article in English | MEDLINE | ID: mdl-26959115

ABSTRACT

p53 is a protein that causes cell cycle arrest, apoptosis or senescence, being crucial in the process of tumor suppression in several cell types. Different in vitro and animal models have been designed for the study of p53 role in skin cancer. These models have revealed opposing results, as in some experimental settings it appears that p53 protects against skin cancer, but in others, the opposite conclusion emerges. We have generated cohorts of mice with efficient p53 deletion restricted to stratified epithelia and control littermates expressing wild type p53 and studied their sensitivity to both chemically-induced and spontaneous tumoral transformation, as well as the tumor types originated in each experimental group. Our results indicate that the absence of p53 in stratified epithelia leads to the appearance, in two-stage skin carcinogenesis experiments, of a higher number of tumors that grow faster and become malignant more frequently than tumors arisen in mice with wild type p53 genotype. In addition, the histological diversity of the tumor type is greater in mice with epidermal p53 loss, indicating the tumor suppressive role of p53 in different epidermal cell types. Aging mice with p53 inactivation in stratified epithelia developed spontaneous carcinomas in skin and other epithelia. Overall, these results highlight the truly protective nature of p53 functions in the development of cancer in skin and in other stratified epithelia.


Subject(s)
Carcinogenesis/pathology , Carcinoma, Squamous Cell/pathology , Epidermis/pathology , Skin Neoplasms/pathology , Tumor Suppressor Protein p53/physiology , 9,10-Dimethyl-1,2-benzanthracene/toxicity , Animals , Apoptosis , Carcinogenesis/metabolism , Carcinogens/toxicity , Carcinoma, Squamous Cell/etiology , Carcinoma, Squamous Cell/metabolism , Cell Proliferation , Cells, Cultured , Epidermis/metabolism , Female , Male , Mice , Mice, Inbred C57BL , Mice, Inbred DBA , Mice, Knockout , Skin Neoplasms/etiology , Skin Neoplasms/metabolism
14.
ScientificWorldJournal ; 2014: 193803, 2014.
Article in English | MEDLINE | ID: mdl-24523631

ABSTRACT

Inhibition of gene expression through siRNAs is a tool increasingly used for the study of gene function in model systems, including transgenic mice. To achieve perdurable effects, the stable expression of siRNAs by an integrated transgenic construct is necessary. For transgenic siRNA expression, promoters transcribed by either RNApol II or III (such as U6 or H1 promoters) can be used. Relatively large amounts of small RNAs synthesis are achieved when using RNApol III promoters, which can be advantageous in knockdown experiments. To study the feasibility of H1 promoter-driven RNAi-expressing constructs for protein knockdown in transgenic mice, we chose IKK1 as the target gene. Our results indicate that constructs containing the H1 promoter are sensitive to the presence of prokaryotic sequences and to transgene position effects, similar to RNApol II promoters-driven constructs. We observed variable expression levels of transgenic siRNA among different tissues and animals and a reduction of up to 80% in IKK1 expression. Furthermore, IKK1 knockdown led to hair follicle alterations. In summary, we show that constructs directed by the H1 promoter can be used for knockdown of genes of interest in different organs and for the generation of animal models complementary to knockout and overexpression models.


Subject(s)
Gene Knockdown Techniques , I-kappa B Kinase/genetics , Promoter Regions, Genetic , RNA Interference , Animals , Cell Line , Gene Expression Regulation , Gene Order , Gene Silencing , Gene Targeting , Humans , Mice , Mice, Transgenic , Phenotype , RNA, Small Interfering
15.
J Invest Dermatol ; 133(7): 1870-8, 2013 Jul.
Article in English | MEDLINE | ID: mdl-23426135

ABSTRACT

CYLD is a tumor-suppressor gene mutated in the skin appendage tumors cylindromas, trichoepitheliomas, and spiradenomas. We have performed in vivo metastasis assays in nude mice and found that the loss of the deubiquitinase function of CYLD in squamous cell carcinoma (SCC) cells greatly enhances the lung metastatic capability of these cells. These metastases showed several characteristics that make them distinguishable from those carrying a functional CYLD, such as robust angiogenesis, increased expression of tumor malignancy markers of SCCs, and a decrease in the expression of the suppressor of metastasis Maspin. Restoration of Maspin expression in the epidermal SCC cells defective in CYLD deubiquitination function significantly reduces their ability to form metastases, thereby suggesting that the decrease in the levels of Maspin expression plays an important role in the acquisition of metastatic potential of these cells. In addition, we have characterized Maspin downregulation in cylindromas, trichoepitheliomas, and spiradenomas carrying functional inactivating mutations of CYLD, also providing an evidence of the correlation between impaired CYLD function and Maspin decreased expression in vivo in human tumors.


Subject(s)
Carcinoma, Squamous Cell/secondary , Cell Transformation, Neoplastic/genetics , Cell Transformation, Neoplastic/pathology , Cysteine Endopeptidases/genetics , Lung Neoplasms/secondary , Mutation/genetics , Skin Neoplasms/pathology , Animals , Carcinoma, Squamous Cell/genetics , Carcinoma, Squamous Cell/metabolism , Cysteine Endopeptidases/metabolism , Deubiquitinating Enzyme CYLD , Disease Models, Animal , Keratin-13/genetics , Keratin-13/metabolism , Keratin-8/genetics , Keratin-8/metabolism , Lung Neoplasms/genetics , Lung Neoplasms/metabolism , Mice , Mice, Nude , Neovascularization, Pathologic/genetics , Serpins/genetics , Serpins/metabolism , Skin/metabolism , Skin/pathology , Skin Neoplasms/genetics , Skin Neoplasms/metabolism , Snail Family Transcription Factors , Transcription Factors/genetics , Transcription Factors/metabolism
16.
J Invest Dermatol ; 133(1): 239-48, 2013 Jan.
Article in English | MEDLINE | ID: mdl-22832494

ABSTRACT

Nonmelanoma skin cancer (NMSC) is by far the most frequent type of cancer in humans. NMSC includes several types of malignancies with different clinical outcomes, the most frequent being basal and squamous cell carcinomas. We have used the Sleeping Beauty transposon/transposase system to identify somatic mutations associated with NMSC. Transgenic mice bearing multiple copies of a mutagenic Sleeping Beauty transposon T2Onc2 and expressing the SB11 transposase under the transcriptional control of regulatory elements from the keratin K5 promoter were treated with TPA, either in wild-type or Ha-ras mutated backgrounds. After several weeks of treatment, mice with transposition developed more malignant tumors with decreased latency compared with control mice. Transposon/transposase animals also developed basal cell carcinomas. Genetic analysis of the transposon integration sites in the tumors identified several genes recurrently mutated in different tumor samples, which may represent novel candidate cancer genes. We observed alterations in the expression levels of some of these genes in human tumors. Our results show that inactivating mutations in Notch1 and Nsd1, among others, may have an important role in skin carcinogenesis.


Subject(s)
Carcinoma, Basal Cell/genetics , Carcinoma, Squamous Cell/genetics , Cell Transformation, Neoplastic/genetics , DNA Transposable Elements/genetics , Mutation , Skin Neoplasms/genetics , Animals , Carcinogens/toxicity , Carcinoma, Basal Cell/pathology , Carcinoma, Squamous Cell/pathology , Carrier Proteins/genetics , DNA Mutational Analysis/methods , Genes, ras/genetics , Histone Methyltransferases , Histone-Lysine N-Methyltransferase , Humans , Intracellular Signaling Peptides and Proteins/genetics , Keratin-15 , Keratin-5/genetics , Mice , Mice, Inbred C57BL , Mice, Inbred DBA , Mice, Transgenic , Nuclear Proteins/genetics , Promoter Regions, Genetic , Receptor, Notch1/genetics , Skin Neoplasms/pathology , Tetradecanoylphorbol Acetate/toxicity , Transposases/genetics
17.
Mol Cancer Res ; 9(10): 1329-38, 2011 Oct.
Article in English | MEDLINE | ID: mdl-21821676

ABSTRACT

Alterations in nuclear factor kappaB (NFκB) signaling have been related with several diseases and importantly also with cancer. Different animal models with increased or diminished NFκB signaling have shown that NFκB subunits and their regulators are relevant to the pathophysiology of different organs and tissues. In particular, both the deletion of the regulatory subunit ß of the kinase of the inhibitor of NFκB (IKKß) and its overexpression in epidermis lead to the development of skin inflammatory diseases not associated with tumoral lesions. In this work, we have studied the consequences of IKKß overexpression in other organs and tissues. We found that elevated IKKß levels led to altered development and functionality of exocrine glands (i.e., mammary glands) in transgenic female mice. In oral epithelia, increased IKKß expression produced lichenoid inflammation with abundant granulocytes, macrophages, and B cells, among other inflammatory cells. This inflammatory phenotype was associated with high incidence of tumoral lesions in oral epithelia, contrary to what was found in skin. Moreover, IKKß also increased the malignant progression of both spontaneous and experimentally induced oral tumors. These results highlight the importance of IKKß in epithelial and glandular homeostasis as well as in oral tumorigenesis and open the possibility that IKKß activity might be implicated in the development of oral cancer in humans.


Subject(s)
Cell Transformation, Neoplastic/metabolism , I-kappa B Kinase/biosynthesis , Mouth Mucosa/pathology , Animals , Cell Transformation, Neoplastic/genetics , Cell Transformation, Neoplastic/pathology , Epithelial Cells/metabolism , Epithelial Cells/pathology , Female , I-kappa B Kinase/genetics , I-kappa B Kinase/metabolism , Immunohistochemistry , Male , Mice , Mice, Transgenic , Mouth Mucosa/metabolism , Phenotype , Signal Transduction , Transfection
18.
PLoS One ; 6(7): e21984, 2011.
Article in English | MEDLINE | ID: mdl-21755017

ABSTRACT

Non-melanoma skin cancer is the most frequent type of cancer in humans. In this study we demonstrate that elevated IKKα expression in murine epidermis increases the malignancy potential of skin tumors. We describe the generation of transgenic mice overexpressing IKKα in the basal, proliferative layer of the epidermis and in the outer root sheath of hair follicles. The epidermis of K5-IKKα transgenic animals shows several alterations such as hyperproliferation, mislocalized expression of integrin-α6 and downregulation of the tumor suppressor maspin. Treatment of the back skin of mice with the mitogenic agent 12-O-tetradecanoylphorbol-13-acetate causes in transgenic mice the appearance of different preneoplastic changes such as epidermal atypia with loss of cell polarity and altered epidermal tissue architecture, while in wild type littermates this treatment only leads to the development of benign epidermal hyperplasia. Moreover, in skin carcinogenesis assays, transgenic mice carrying active Ha-ras (K5-IKKα-Tg.AC mice) develop invasive tumors, instead of the benign papillomas arising in wild type-Tg-AC mice also bearing an active Ha-ras. Therefore we provide evidence for a tumor promoter role of IKKα in skin cancer, similarly to what occurs in other neoplasias, including hepatocarcinomas and breast, prostate and colorectal cancer. The altered expression of cyclin D1, maspin and integrin-α6 in skin of transgenic mice provides, at least in part, the molecular bases for the increased malignant potential found in the K5-IKKα skin tumors.


Subject(s)
Epidermis/enzymology , Epidermis/pathology , I-kappa B Kinase/metabolism , Skin Neoplasms/pathology , Animals , Biomarkers, Tumor/metabolism , Cattle , Cell Proliferation/drug effects , Epidermis/drug effects , Immunohistochemistry , Integrin alpha6/metabolism , Keratinocytes/drug effects , Keratinocytes/enzymology , Keratinocytes/pathology , Mice , Mice, Transgenic , NF-kappa B/metabolism , Rabbits , Serpins/metabolism , Signal Transduction/drug effects , Skin Neoplasms/enzymology , Tetradecanoylphorbol Acetate/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...